We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Liquid Biopsy Panel Targets Pediatric Cancers

By LabMedica International staff writers
Posted on 21 Nov 2024

Identifying mutations in a child's cancer using advanced sequencing technologies can significantly improve treatment outcomes. More...

By understanding the specific cancer-causing mutations in each patient, physicians can tailor targeted therapies to address those mutations. However, current whole genome sequencing technology requires extensive physical and computational resources that many institutions do not have access to. To overcome this challenge, researchers have developed a more focused panel that targets a smaller set of genes known to play a role in childhood cancers, instead of sequencing the entire genome. This panel is capable of diagnosing over 90% of pediatric cancer patients by sequencing just 0.15% of the human genome, providing a cost-effective method for testing and classifying childhood cancers and helping guide treatment.

The SJPedPanel, developed by scientists at St. Jude Children’s Research Hospital (Memphis, TN, USA), is specifically designed for pediatric cancer samples, focusing on genes that are well-known to be involved in childhood cancers. Unlike other genetic panels, which are typically designed for adult cancers and then adapted for children, the SJPedPanel was developed with a pediatric focus from the start. The team also considered practical challenges in detecting certain mutations, selecting the most informative genes for inclusion. This approach led to significant improvements compared to existing cancer gene panels. The panel’s performance and validation were detailed in Clinical Cancer Research.

Not only does the SJPedPanel outperform adult-focused panels, but it also surpasses the gold-standard whole genome sequencing in some cases. Whole genome sequencing analyzes the entire genome, which can be challenging for detecting cancers with low cell counts due to the need for high-depth sampling. The panel’s success is partly due to its unique design and origin. St. Jude was involved in the Pediatric Cancer Genome Project, which sequenced hundreds of pediatric patients, providing a comprehensive understanding of the genomic landscape of childhood cancers. This initiative focused on pediatric cancers, which are genetically distinct from adult cancers.

The impact of the SJPedPanel could be significant for patients worldwide. Early and accurate diagnosis of childhood cancers is critical for guiding treatment and improving outcomes. Whole genome sequencing, however, requires costly infrastructure that many institutions cannot afford. By using this more affordable panel, healthcare facilities without the necessary resources can still identify and diagnose these cancers. While the panel will be commercially available, St. Jude plans to openly share its design and knowledge to help as many children as possible.

“We have performed clinical genomics for quite a few years and one of the challenges is diagnosing every tumor, especially those with a low percentage of cancer cells in the tested sample.” said co-corresponding author Xiaotu Ma, PhD, St. Jude Department of Computational Biology. “So, we created SJPedPanel as a summary to concentrate most of the genetic knowledge we have gained in the last decade into one smaller test that can be used clinically.”

Related Links:
St. Jude Children’s Research Hospital


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.